보고서 요약(국문)

개요
전 세계 지방산 산화 장애 치료제 시장은 2022년 XX억 달러에 달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률로 2030년에는 XX억 달러에 이를 것으로 예상됩니다.
지방산 산화 장애(FAOD), 또는 지방산 산화 결핍이나 지방산 대사 장애라고도 불리는 이 질환은 신체가 지방을 분해하여 에너지로 전환하는 능력을 저해하는 드문 유전성 대사 질환입니다. 일반적으로 신체는 특히 단식 중이거나 격렬한 운동을 할 때 지방산을 주요 에너지원으로 사용합니다. 반면, FAOD 환자는 지방산 산화 경로에 관여하는 효소 또는 운반 단백질 중 하나 이상이 결핍되어 있습니다.
지방산 산화 장애(FAOD) 치료제는 FAOD와 관련된 증상 및 결과를 관리하고 완화하는 데 사용되는 약물 치료 및 요법입니다. 이러한 약물은 에너지 생산을 증진하고, 독성 대사산물 축적을 방지하며, 근육 약화, 저혈당, 대사 위기 등의 증상을 치료하는 것을 목표로 합니다.
시장 동향: 성장 동력 및 제약 요인
제품 승인 건수 증가
제품 승인 건수가 증가함에 따라 지방산 산화 장애(FAOD) 치료제 시장이 성장할 것으로 예상됩니다. 각 승인은 치료 선택의 폭을 넓히고, 환자의 접근성을 개선하며, 경쟁을 촉진하고, 투자자의 신뢰를 높이기 때문입니다. 이러한 승인은 엄격한 임상 시험의 결과이며, 환자에게 최첨단 의약품을 제공하는 동시에 추가적인 연구 개발 투자를 유도합니다.

예를 들어, 희귀 유전성 미토콘드리아 질환 환자를 위한 치료제 개발 및 상용화에 주력하는 임상 단계 제약 회사인 레네오 파마슈티컬스(Reneo Pharmaceuticals, Inc.)는 2023년 1월, 미국 식품의약국(FDA)이 장쇄 3-하이드록시아실-CoA 탈수소효소(LCHAD) 결핍증 치료제인 마보델파르(REN001)에 대해 신속심사(Fast Track) 지정을 승인했다고 발표했습니다. LCHAD 결핍증은 장쇄 지방산 산화 장애(LC-FAOD) 환자에게서 흔히 나타나는 유전자형 중 하나입니다. 따라서 위와 같은 요인들로 인해 시장은 예측 기간 동안 성장세를 보일 것으로 예상됩니다.
시장 동향: 제약 요인
지방산 산화 장애(FAOD) 치료제 시장의 주요 제약 요인은 환자 수가 제한적이라는 점입니다. 흔한 질병에 비해 이러한 드문 유전성 대사 이상은 소수의 사람들에게만 영향을 미칩니다. 결과적으로 제약 회사들은 FAOD 특이적 약물 및 치료법의 연구, 개발 및 생산에서 규모의 경제와 수익성을 확보하는 데 어려움을 겪습니다. 제한된 경쟁과 규모의 경제로 인해 시장 규모가 작아 기업들이 지방산 산화 장애(FAOD) 치료제 연구에 상당한 자원을 투자할 재정적 유인이 줄어들고, 결과적으로 치료 선택지가 제한되고 환자의 치료 비용이 증가할 수 있습니다.
세분화 분석
전 세계 지방산 산화 장애 치료제 시장은 유형, 약물 종류, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
트리헵타노인 부문은 지방산 산화 장애 치료제 시장 점유율의 약 31.2%를 차지했습니다.
트리헵타노인 부문은 31.2%의 시장 점유율로 지방산 산화 장애(FAOD) 치료제 시장을 주도할 것으로 예상됩니다. 대사 조절제인 트리헵타노인은 장쇄 지방산 산화 장애 및 기타 형태의 지방산 산화 장애에 대한 잠재적으로 효과적인 치료제로 상당한 관심을 받고 있습니다. 이는 대체 에너지원으로 작용하여 지방산 산화 장애로 인한 대사 문제를 예방하는 데 도움을 줍니다.
또한, 이 약물에 대한 제품 승인 건수 증가와 기업 간 협력 증가는 해당 부문의 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2020년 7월 울트라제닉스 제약(Ultrageneyx Pharmaceutical Inc.)은 희귀 질환 및 치료가 어려운 질환 환자를 전문으로 하는 저명한 독립 전국 전문 약국인 오르시니 제약 서비스(Orsini Pharmaceutical Services)와 도졸비(트리헵타노인)의 제한적 유통 전문 약국 파트너 계약을 체결했습니다. 도졸비는 분자적으로 장쇄 지방산 산화 장애(LC-FAOD)가 확인된 소아 및 성인 환자의 칼로리 및 지방산 공급원 치료제로 승인되었습니다. 따라서 위와 같은 요인들로 인해 해당 부문은 예측 기간 동안 시장을 주도할 것으로 예상됩니다.
지리적 시장 침투
북미는 2022년 시장 점유율의 약 37.4%를 차지했습니다.
특히 미국을 중심으로 한 북미 지역은 제품 승인 증가, 임상 시험 건수 증가, 주요 시장 참여 기업의 존재 등의 요인으로 시장을 주도할 것으로 예상됩니다.
예를 들어, 희귀 및 초희귀 질환 치료를 위한 신약 개발 및 상용화에 주력하는 바이오제약 회사인 울트라제닉스 파마슈티컬(Ultragenyx Pharmaceutical Inc.)은 2020년 6월, 분자적으로 확인된 장쇄 지방산 산화 장애(LC-FAOD)를 가진 소아 및 성인 환자 치료를 위한 칼로리 및 지방산 공급원인 도졸비(트리헵타노인)에 대해 FDA 승인을 획득하여 최초로 승인된 치료제가 되었습니다.
또한, 아시아 태평양 지역 국가들의 의료비 지출 증가, 인구 증가, 질병에 대한 인식 제고, 정부의 인식 제고 정책, 그리고 치료 수요 증가는 아시아 태평양 지역 시장 매출 성장에 기여하는 주요 요인입니다.

COVID-19 영향 분석
COVID-19 팬데믹은 지방산 산화 장애(FAOD) 치료제 시장에 큰 영향을 미쳤습니다. 진행 중인 임상 시험에서 환자 등록 및 데이터 수집이 지연되었고, 공급망 문제로 FAOD 치료제 제조 및 유통이 차질을 빚어 잠재적인 공급 부족 사태가 발생했습니다. COVID-19 관리에 자원이 집중되면서 의료 우선순위가 바뀌었고, 이로 인해 FAOD와 같은 희귀 질환에 대한 관심과 자금 지원이 줄어들었습니다. 봉쇄 및 제한 조치로 진단과 치료가 지연되면서 FAOD 환자들에게 위험이 초래되었습니다.
특히 기저 질환을 가진 FAOD 환자들은 일상생활에서 추가적인 위험과 어려움을 겪었습니다. 그러나 한 연구에서 지방산 합성의 약리학적 억제가 SARS-CoV-2 복제를 차단한다는 사실이 밝혀졌고, 지방산 합성효소 억제제가 COVID-19 예방 및 치료를 위한 약물 후보로 제시되었습니다.

시장 세분화
유형별
• 단쇄 지방산 산화 장애 치료제
• 중쇄 지방산 산화 장애 치료제
• 장쇄 지방산 산화 장애 치료제
• 초장쇄 지방산 산화 장애 치료제
약물 종류별
• 레보카르니틴
• 트리헵타노인
• 덱스트로스
• 리보플라빈
• 기타
투여 경로별
• 경구
• 정맥 주사
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
지방산 산화 장애 치료제 시장의 주요 글로벌 업체로는 Pfizer Inc. 등이 있습니다. Leadiant Biosciences, Inc., Ultragenyx Pharmaceutical Inc., Vitane Pharmaceuticals, Inc., Laboratorios Casasco, NEXTWELL PHARMACEUTICAL PRIVATE LIMITED, Action Labs, Inolex, Inc., Lonza Group Ltd, Northeast Pharmaceutical Group Co., Ltd. 등이 포함됩니다.
주요 개발 사항
• 희귀 유전성 미토콘드리아 질환 환자를 위한 치료제 개발 및 상용화에 주력하는 임상 단계 제약 회사인 Reneo Pharmaceuticals, Inc.는 2023년 1월 31일, 미국 식품의약국(FDA)이 장쇄 3-하이드록시아실-CoA 탈수소효소(LCHAD) 결핍증 치료제인 마보델파르(REN001)를 신속심사(Fast Track) 대상으로 지정했다고 발표했습니다. LCHAD 결핍증은 장쇄 지방산 산화 장애(LC-FAOD) 환자에게서 흔히 나타나는 유전자형 중 하나입니다.
보고서 구매 이유

• 유형, 약물 유형, 투여 경로, 유통 채널 및 지역별 글로벌 지방산 산화 장애 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 지방산 산화 장애 치료제 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 지방산 산화 장애 치료제 시장 보고서는 약 69개의 표, 69개의 그림, 195페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Fatty Acid Oxidation Disorder Drugs Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.
Fatty Acid Oxidation Disorders (FAOD), also known as fatty acid oxidation deficits or fatty acid metabolism disorders, are a category of rare hereditary metabolic diseases that halt the body's ability to break down and turn fats into energy. Normally, the body uses fatty acids as its primary source of energy, especially when fasting or engaging in intense physical exercise. Individuals with FAODs, on the other hand, are deficient in one or more of the enzymes or transport proteins involved in the fatty acid oxidation pathway.
Fatty Acid Oxidation Disorders (FAOD) drugs are pharmaceutical treatments and therapies that are used to manage and mitigate the symptoms and consequences associated with FAOD. These medications are intended to enhance energy production, prevent toxic metabolite buildup, and treat symptoms such as muscle weakness, hypoglycemia, and metabolic crises.
Market Dynamics: Drivers and Restraints
The increasing number of product approvals
The increasing number of product approvals is expected to drive the fatty acid oxidation disorder (FAOD) drug market, as each approval extends treatment options, improves patient access, encourages competition, and boosts investor confidence. These approvals are the outcome of rigorous clinical trials, which provide patients with cutting-edge medicines while also driving additional R&D investments.
For instance, in January 2023, Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, stated that the US Food and Drug Administration (FDA) has granted mavodelpar (REN001) Fast Track designation for long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, one of the predominant genotypes in patients with long-chain fatty acid oxidation disorder (LC-FAOD). Thus, owing to the above factors the market is expected to drive over the forecast period.
Market Dynamics: Restraint
The limited patient pool is a major restraint to the fatty acid oxidation disorders (FAOD) drugs market. In comparison to more prevalent diseases, these uncommon hereditary metabolic abnormalities affect a small percentage of people. As a result, pharmaceutical companies face difficulties in establishing economies of scale and profitability in the research, development, and production of FAOD-specific drugs and therapies. Due to restricted competition and economies of scale, the small market size reduces financial incentives for companies to invest significant resources in FAOD drug research, potentially resulting in fewer treatment options and higher costs for patients.
Segment Analysis
The global fatty acid oxidation disorder drugs market is segmented based on type, drug type, route of administration, distribution channel and region.
The triheptanoin segment accounted for approximately 31.2% of the fatty acid oxidation disorder drugs market share
Triheptanoin segment is expected to dominate the fatty acid oxidation disorder (FAOD) drug market with market share of 31.2%. Triheptanoin, a metabolic modulator, has received considerable interest as a potentially effective treatment for long-chain FAODs and other forms of FAODs. It serves as an alternative energy source and aids in avoiding the metabolic problems caused by FAODs.
Furthermore, the increasing number product approvals and collaboration between the companies for this drug is expected to fuel the segment growth. For instance, in July 2020, Ultragenyx Pharmaceutical Inc. partnered with Orsini Pharmaceutical Services, a prominent independent national specialty pharmacy specializing in patients with rare and difficult disorders, as a limited distribution specialty pharmacy partner for Dojolvi (triheptanoin). Dojolvi is approved for the treatment of pediatric and adult patients with molecularly proven long-chain fatty acid oxidation disorders (LC-FAOD) as a source of calories and fatty acids. Thus, owing to the above factors the segment is expected to dominate over the forecast period.
Geographical Penetration
North America accounted for approximately 37.4% of the market share in 2022
The North America region particulary the U.S. is expected to dominate the market owing to the factors such as, rise in product approvals, increasing number of clinical trial, and presence of key market players in this region
For instance, in June 2020, Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, received FDA approval for Dojolvi (triheptanoin) as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD) as the first approved therapy.
Moreover, the increasing healthcare spending and growing population and awareness in Asia Pacific countries and government initiatives to promote awareness, and rise in the demand for the treatment are some of the other factors responsible for revenue growth of the market in the Asia Pacific region.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a major impact on the market for Fatty Acid Oxidation Disorder (FAOD) drugs. It caused delays in patient enrollment and data collecting in ongoing clinical trials. Manufacturing and distribution of FAOD medications were hampered by supply chain issues, potentially leading to shortages. Healthcare priorities have evolved, with resources allocated to COVID-19 management, affecting attention and funding for uncommon diseases such as FAODs. Due to lockdowns and limitations, diagnoses and treatments were delayed, creating hazards to FAOD patients.
FAOD patients, many of whom had underlying medical issues, faced additional risks and disturbances in their everyday lives. However, A study found that pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication, and identified fatty acid synthase inhibitors as drug candidates for the prevention and treatment of COVID-19.
Market Segmentation
By Type
• Short-Chain FAODs
• Medium-Chain FAODs
• Long-Chain FAODs
• Very Long-Chain FAODs
By Drug Type
• Levocarnitine
• Triheptanoin
• Dextrose
• Riboflavin
• Others
By Route of Administration
• Oral
• Intravenous
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the fatty acid oxidation disorder drugs market include Pfizer Inc., Leadiant Biosciences, Inc., Ultragenyx Pharmaceutical Inc., Vitane Pharmaceuticals, Inc., Laboratorios Casasco, NEXTWELL PHARMACEUTICAL PRIVATE LIMITED, Action Labs, Inolex, Inc., Lonza Group Ltd, Northeast Pharmaceutical Group Co., Ltd., and among others.
Key Developments
• On January 31, 2023, Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, stated that the US Food and Drug Administration (FDA) has granted mavodelpar (REN001) Fast Track designation for long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, one of the predominant genotypes in patients with long-chain fatty acid oxidation disorder (LC-FAOD).
Why Purchase the Report?
• To visualize the global fatty acid oxidation disorder drugs market segmentation based on type, drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of fatty acid oxidation disorder drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.
The global fatty acid oxidation disorder drugs market report would provide approximately 69 tables, 69 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Drug Type
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. he increasing number of product approvals
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. The availability of limited patient pool
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Epidemiology
5.2. Porter's Five Force Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Pipeline Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Short-Chain FAODs*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Medium-Chain FAODs
7.4. Long-Chain FAODs
7.5. Very Long-Chain FAODs
8. By Drug Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index, By Drug Type
8.2. Levocarnitine*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Triheptanoin
8.4. Dextrose
8.5. Riboflavin
8.6. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Intravenous
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Spain
11.3.7.5. Italy
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Pfizer Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Leadiant Biosciences, Inc.
13.3. Ultragenyx Pharmaceutical Inc.
13.4. Vitane Pharmaceuticals, Inc.
13.5. Laboratorios Casasco
13.6. NEXTWELL PHARMACEUTICAL PRIVATE LIMITED
13.7. Action Labs
13.8. Inolex, Inc.
13.9. Lonza Group Ltd
13.10. Northeast Pharmaceutical Group Co., Ltd.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Pfizer Inc., 4.	Key Developments, Leadiant Biosciences, Inc., Ultragenyx Pharmaceutical Inc., Vitane Pharmaceuticals, Inc., Laboratorios Casasco, NEXTWELL PHARMACEUTICAL PRIVATE LIMITED, Action Labs, Inolex, Inc., Lonza Group Ltd, Northeast Pharmaceutical Group Co., Ltd.

표 목록 (Tables)

List of Tables

Table 1 Global Fatty Acid Oxidation Disorder Drugs Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Fatty Acid Oxidation Disorder Drugs Market Value, By Drug Type, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Fatty Acid Oxidation Disorder Drugs Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Fatty Acid Oxidation Disorder Drugs Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Fatty Acid Oxidation Disorder Drugs Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Fatty Acid Oxidation Disorder Drugs Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Fatty Acid Oxidation Disorder Drugs Market Value, By Type, 2022-2031 (US$ Million)

Table 8 Global Fatty Acid Oxidation Disorder Drugs Market Value, By Drug Type, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Fatty Acid Oxidation Disorder Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 10 Global Fatty Acid Oxidation Disorder Drugs Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 11 Global Fatty Acid Oxidation Disorder Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 12 Global Fatty Acid Oxidation Disorder Drugs Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 13 Global Fatty Acid Oxidation Disorder Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 14 Global Fatty Acid Oxidation Disorder Drugs Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 15 Global Fatty Acid Oxidation Disorder Drugs Market Value, By Region, 2022-2031 (US$ Million)

Table 16 North America Fatty Acid Oxidation Disorder Drugs Market Value, By Type, 2022-2031 (US$ Million)

Table 17 North America Fatty Acid Oxidation Disorder Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 18 North America Fatty Acid Oxidation Disorder Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 19 North America Fatty Acid Oxidation Disorder Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 North America Fatty Acid Oxidation Disorder Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 21 South America Fatty Acid Oxidation Disorder Drugs Market Value, By Type, 2022-2031 (US$ Million)

Table 22 South America Fatty Acid Oxidation Disorder Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 23 South America Fatty Acid Oxidation Disorder Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 24 South America Fatty Acid Oxidation Disorder Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 25 South America Fatty Acid Oxidation Disorder Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 26 Europe Fatty Acid Oxidation Disorder Drugs Market Value, By Type, 2022-2031 (US$ Million)

Table 27 Europe Fatty Acid Oxidation Disorder Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 28 Europe Fatty Acid Oxidation Disorder Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 29 Europe Fatty Acid Oxidation Disorder Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 30 Europe Fatty Acid Oxidation Disorder Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 31 Asia-Pacific Fatty Acid Oxidation Disorder Drugs Market Value, By Type, 2022-2031 (US$ Million)

Table 32 Asia-Pacific Fatty Acid Oxidation Disorder Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 33 Asia-Pacific Fatty Acid Oxidation Disorder Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 34 Asia-Pacific Fatty Acid Oxidation Disorder Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 35 Asia-Pacific Fatty Acid Oxidation Disorder Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 36 Middle East & Africa Fatty Acid Oxidation Disorder Drugs Market Value, By Type, 2022-2031 (US$ Million)

Table 37 Middle East & Africa Fatty Acid Oxidation Disorder Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 38 Middle East & Africa Fatty Acid Oxidation Disorder Drugs Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 39 Middle East & Africa Fatty Acid Oxidation Disorder Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 40 Pfizer Inc.: Overview

Table 41 Pfizer Inc.: Product Portfolio

Table 42 Pfizer Inc.: Key Developments

Table 43 Leadiant Biosciences, Inc.: Overview

Table 44 Leadiant Biosciences, Inc.: Product Portfolio

Table 45 Leadiant Biosciences, Inc.: Key Developments

Table 46 Ultragenyx Pharmaceutical Inc.: Overview

Table 47 Ultragenyx Pharmaceutical Inc.: Product Portfolio

Table 48 Ultragenyx Pharmaceutical Inc.: Key Developments

Table 49 Vitane Pharmaceuticals, Inc.: Overview

Table 50 Vitane Pharmaceuticals, Inc.: Product Portfolio

Table 51 Vitane Pharmaceuticals, Inc.: Key Developments

Table 52 Laboratorios Casasco: Overview

Table 53 Laboratorios Casasco: Product Portfolio

Table 54 Laboratorios Casasco: Key Developments

Table 55 NEXTWELL PHARMACEUTICAL PRIVATE LIMITED: Overview

Table 56 NEXTWELL PHARMACEUTICAL PRIVATE LIMITED: Product Portfolio

Table 57 NEXTWELL PHARMACEUTICAL PRIVATE LIMITED: Key Developments

Table 58 Action Labs: Overview

Table 59 Action Labs: Product Portfolio

Table 60 Action Labs: Key Developments

Table 61 Inolex, Inc.: Overview

Table 62 Inolex, Inc.: Product Portfolio

Table 63 Inolex, Inc.: Key Developments

Table 64 Lonza Group Ltd: Overview

Table 65 Lonza Group Ltd: Product Portfolio

Table 66 Lonza Group Ltd: Key Developments

Table 67 Northeast Pharmaceutical Group Co., Ltd.: Overview

Table 68 Northeast Pharmaceutical Group Co., Ltd.: Product Portfolio

Table 69 Northeast Pharmaceutical Group Co., Ltd.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 2 Global Fatty Acid Oxidation Disorder Drugs Market Share, By Type, 2022 & 2031 (%)

Figure 3 Global Fatty Acid Oxidation Disorder Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 4 Global Fatty Acid Oxidation Disorder Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 5 Global Fatty Acid Oxidation Disorder Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 6 Global Fatty Acid Oxidation Disorder Drugs Market Share, By Region, 2022 & 2031 (%)

Figure 7 Global Fatty Acid Oxidation Disorder Drugs Market Y-o-Y Growth, By Type, 2022-2031 (%)

Figure 8 Short-Chain FAODs Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 9 Medium-Chain FAODs Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 10 Long-Chain FAODs Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 11 Very Long-Chain FAODs Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 12 Global Fatty Acid Oxidation Disorder Drugs Market Y-o-Y Growth, By Drug Type, 2022-2031 (%)

Figure 13 Levocarnitine Drug Type in Global Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 14 Triheptanoin Drug Type in Global Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 15 Dextrose Drug Type in Global Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 16 Riboflavin Drug Type in Global Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 17 Others Drug Type in Global Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 18 Global Fatty Acid Oxidation Disorder Drugs Market Y-o-Y Growth, By Route of Administration, 2022-2031 (%)

Figure 19 Oral Route of Administration in Global Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 20 Intravenous Route of Administration in Global Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 21 Global Fatty Acid Oxidation Disorder Drugs Market Y-o-Y Growth, By Distribution Channel, 2022-2031 (%)

Figure 22 Hospital Pharmacies Distribution Channel in Global Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 23 Retail Pharmacies Distribution Channel in Global Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 24 Online Pharmacies Distribution Channel in Global Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 25 Global Fatty Acid Oxidation Disorder Drugs Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 26 North America Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 27 Asia-Pacific Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 28 Europe Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 29 South America Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 30 Middle East and Africa Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 31 North America Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 32 North America Fatty Acid Oxidation Disorder Drugs Market Share, By Type, 2022 & 2031 (%)

Figure 33 North America Fatty Acid Oxidation Disorder Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 34 North America Fatty Acid Oxidation Disorder Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 35 North America Fatty Acid Oxidation Disorder Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 36 North America Fatty Acid Oxidation Disorder Drugs Market Share, By Country, 2022 & 2031 (%)

Figure 37 South America Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 38 South America Fatty Acid Oxidation Disorder Drugs Market Share, By Type, 2022 & 2031 (%)

Figure 39 South America Fatty Acid Oxidation Disorder Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 40 South America Fatty Acid Oxidation Disorder Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 41 South America Fatty Acid Oxidation Disorder Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 42 South America Fatty Acid Oxidation Disorder Drugs Market Share, By Country, 2022 & 2031 (%)

Figure 43 Europe Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 44 Europe Fatty Acid Oxidation Disorder Drugs Market Share, By Type, 2022 & 2031 (%)

Figure 45 Europe Fatty Acid Oxidation Disorder Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 46 Europe Fatty Acid Oxidation Disorder Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 47 Europe Fatty Acid Oxidation Disorder Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 48 Europe Fatty Acid Oxidation Disorder Drugs Market Share, By Country, 2022 & 2031 (%)

Figure 49 Asia-Pacific Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 50 Asia-Pacific Fatty Acid Oxidation Disorder Drugs Market Share, By Type, 2022 & 2031 (%)

Figure 51 Asia-Pacific Fatty Acid Oxidation Disorder Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 52 Asia-Pacific Fatty Acid Oxidation Disorder Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 53 Asia-Pacific Fatty Acid Oxidation Disorder Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 54 Asia-Pacific Fatty Acid Oxidation Disorder Drugs Market Share, By Country, 2022 & 2031 (%)

Figure 55 Middle East & Africa Fatty Acid Oxidation Disorder Drugs Market Value, 2022-2031 (US$ Million)

Figure 56 Middle East & Africa Fatty Acid Oxidation Disorder Drugs Market Share, By Type, 2022 & 2031 (%)

Figure 57 Middle East & Africa Fatty Acid Oxidation Disorder Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 58 Middle East & Africa Fatty Acid Oxidation Disorder Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 59 Middle East & Africa Fatty Acid Oxidation Disorder Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 60 Pfizer Inc.: Financials

Figure 61 Leadiant Biosciences, Inc.: Financials

Figure 62 Ultragenyx Pharmaceutical Inc.: Financials

Figure 63 Vitane Pharmaceuticals, Inc.: Financials

Figure 64 Laboratorios Casasco: Financials

Figure 65 NEXTWELL PHARMACEUTICAL PRIVATE LIMITED: Financials

Figure 66 Action Labs: Financials

Figure 67 Inolex, Inc.: Financials

Figure 68 Lonza Group Ltd: Financials

Figure 69 Northeast Pharmaceutical Group Co., Ltd.: Financials

세계 지방산 산화 장애 치료제 시장 – 2023-2030

Global Fatty Acid Oxidation Disorder Drugs Market - 2023-2030